Increase Safety and Viability of ADC-Based Anticancer Therapeutics With Antibody Specificity Screening
Antibody drug conjugates (ADCs) are an exciting and growing class of anticancer therapeutics. Unlike many cancer treatment options, ADC therapies have the potential to find and destroy cancer cells without causing collateral damage to healthy cells. A monoclonal antibody (mAb) is used to bind with cancer cells and deliver a cytotoxic payload directly to a tumor. This innovative treatment hinges crucially on highly specific binding to ensure that cancer cells are neutralized, while healthy cells are left unaffected by the payload of the ADC.
Antibody specificity screening via the Retrogenix® Cell Microarray platform offers a unique opportunity to test for both antibody and payload derived off-target binding during the Discovery phase. Underpinning the technology is the largest and highest quality protein library of its kind. ADCs are screened against over 6,500 full-length human plasma, secreted and heterodimeric proteins, including > 98% of human cell surface proteins present during 10-18 weeks of pregnancy.
Increase Candidate Confidence
The Retrogenix® Cell Microarray enables clients to assess the binding specificity of both the antibody scaffold and cytotoxic payload of an ADC, providing comprehensive insight into off-target activity. Antibody specificity screening during the Discovery phase helps to identify non-viable candidates before they enter the clinic, reducing the risk of later stage attrition. The Retrogenix® platform generates IND-enabling data, supporting regulatory application and increasing safety confidence.
Retrogenix® screening is performed using biosynthesized proteins overexpressed individually on the surface of lab-grown cells and does not use nor rely on human tissue or animal research models, removing the associated costs and lead times of ethical approval.